Embecta Q4 2024 Earnings Report $19.82 -0.17 (-0.85%) (As of 12/17/2024 ET) Earnings HistoryForecast Embecta EPS ResultsActual EPS$0.45Consensus EPS $0.40Beat/MissBeat by +$0.05One Year Ago EPS$0.59Embecta Revenue ResultsActual Revenue$286.10 millionExpected Revenue$276.97 millionBeat/MissBeat by +$9.13 millionYoY Revenue Growth+1.50%Embecta Announcement DetailsQuarterQ4 2024Date11/26/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseEMBC Earnings HistorySlide DeckFull Screen Slide DeckPowered by How to piss off your liberal friends… and profit from it (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Embecta Earnings HeadlinesEmbecta (NASDAQ:EMBC) and PAVmed (NASDAQ:PAVM) Critical AnalysisDecember 14, 2024 | americanbankingnews.comContrasting Embecta (NASDAQ:EMBC) and QHSLab (OTCMKTS:USAQ)December 13, 2024 | americanbankingnews.comHiding in the Bible New documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.December 18, 2024 | Porter & Company (Ad)BTIG upgrades Embecta Corporation (EMBC) to a BuyDecember 11, 2024 | markets.businessinsider.comHere Is Why Bargain Hunters Would Love Fast-paced Mover Embecta Corp. (EMBC)December 9, 2024 | msn.comNew Initiatives Expected To Make Embecta More ProfitableDecember 4, 2024 | seekingalpha.comSee More Embecta Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Embecta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Embecta and other key companies, straight to your email. Email Address About EmbectaEmbecta (NASDAQ:EMBC), a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.View Embecta ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
